Skip to main content

Table 1 Characteristics of the patients with IL28B C/C and IL28B T* genotypes.

From: The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

Characteristics

IL28B C/C

IL28B T*

All HCV patients

Number of Patients

23

33

56

Sex-Female

6 (26.1%)

15 (45.5%)

21 (37.5%)

Age

49.9 ± 4.4

47.5 ± 6.7

48.52 ± 5.96

Race, African American (#)

1 (4.3%)

8 (24.2%)

9 (16.1%)

Cirrhosis

5(22.7%)

8(25.0%)

13 (24.1%)

Obesity

13(56.5%)

16(48.5%)

29(51.8%)

Diabetes mellitus

1(4.3%)

5(15.2%)

6(10.7%)

HCV genotype 1

16 (65.2%)

27 (81.8%)

43(76.8%)

Pretreatment ALT

96 ± 59

111 ± 79

104 ± 72

Pretreatment HCV RNA (IU/mL)

5,596,354 ± 6,524,048

4,424,606 ± 5,295,969

4,893,305 ± 5,788,661

High Viral Load (> 850,000 IU/mL)

17 (77.3%)

25 (75.8%)

42 (76.4%)

No Complete EVR (p < 4.27 e-05)

3 (13%)

22 (68.8%)

25 (45.5%)

No EVR (p < 0.005)

1 (4.3%)

12 (37.5%)

13 (26.3%)

Sustained Virologic Response (p < 0.0022)

15 (65.2%)

8 (24.2%)

23 (41.1%)